Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 220

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14–Mutant NSCLC

Recondo, Gonzalo, Bahcall, Magda, Spurr, Liam F., Che, Jianwei, Ricciuti, Biagio, Leonardi, Giulia C., Lo, Ying-Chun, Li, Yvonne Y., Lamberti, Giuseppe, Nguyen, Tom, Milan, Marina S.D., Venkatraman, Deepti, Umeton, Renato, Paweletz, Cloud P., Albayrak, Adem, Cherniack, Andrew D., Price, Kristin S., Fairclough, Stephen R., Nishino, Mizuki, Sholl, Lynette M., Oxnard, Geoffrey R., Jänne, Pasi A., Awad, Mark M. · 2020 · Clinical Cancer Research

Abstract

Purpose: Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors (TKI) are poorly understood. We aimed to characterize the genomic mechanisms of resistance to type I and type II MET TKIs and their impact on sequential MET TKI therapy outcomes in patients with metastatic MET exon 14–mutant NSCLC. Experimental Design: Genomic alterations occurring at the time of progression on MET TKIs were studied using plasma and tissue next-generation sequencing (NGS). Results: A total of 20 patients had tissue or plasma available for analysis at the time of acquired resistance to a MET TKI. Genomic alterations known or suspected to be mechanisms of resistance were detected in 15 patients (75%). On-target acquired mechanisms of resistance, including single and polyclonal MET kinase domain mutations in codons H1094, G1163, L1195, D1228, Y1230, and high levels of amplification of the MET exon 14–mutant allele, were observed in 7 patients (35%). A number of off-target mechanisms of resistance were detected in 9 patients (45%), including KRAS mutations and amplifications in KRAS, EGFR, HER3, and BRAF; one case displayed both on- and off-target mechanisms of resistance. In 2 patients with on-target resistant mutations, switching between type I and type II MET TKIs resulted in second partial responses. Conclusions: On-target secondary mutations and activation of bypass signaling drive resistance to MET TKIs. A deeper understanding of these molecular mechanisms can support the development of sequential or combinatorial therapeutic strategies to overcome resistance.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-19-3608

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 220

Metadata

Authors
Recondo, G., Bahcall, M., Spurr, L. F., Che, J., Ricciuti, B., Leonardi, G. C., Lo, Y.-C., Li, Y. Y., Lamberti, G., Nguyen, T., Milan, M. S. D., Venkatraman, D., Umeton, R., Paweletz, C. P., Albayrak, A., Cherniack, A. D., Price, K. S., Fairclough, S. R., Nishino, M., Sholl, L. M., Oxnard, G. R., Jänne, P. A., & Awad, M. M.
Venue
Clinical Cancer Research
Published
2020-06-01
Volume
26
Issue
11
Pages
2615-2625
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W3004655782
Cited by
220
References
7
FWCI
15.52
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14–Mutant NSCLC. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-19-3608
The paper
Recondo, G., Bahcall, M., Spurr, L. F., Che, J., Ricciuti, B., Leonardi, G. C., Lo, Y.-C., Li, Y. Y., Lamberti, G., Nguyen, T., Milan, M. S. D., Venkatraman, D., Umeton, R., Paweletz, C. P., Albayrak, A., Cherniack, A. D., Price, K. S., Fairclough, S. R., Nishino, M., . . . Awad, M. M. (2020). Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14–Mutant NSCLC. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-19-3608

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.